Phase 2 clinical trial for MT-7117 EPP
Do you have Erythropoietic Protoporphyria (EPP)?
We need you to participate in research! Get involved TODAY!
Phase 2 clinical trial for MT-7117, an investigational drug for EPP, has begun. This trial is being conducted to assess
effectiveness and safety of an oral investigational drug on sunlight exposure duration and tolerance in individuals
If you are interested in participating in this exciting new trial, contact the APF on 1.866.APF.3635 or
email@example.com. Subjects must have a confirmed diagnosis of EPP based on medical history and
be between 18-70 years of age at screening. Participants must be willing to travel to the study site for all scheduled
visits and be willing to cooperate and comply with the protocol restrictions and requirements. Exclusion criteria
apply and may be discussed with the study site.
Each Step Toward Finding an Effective Treatment is Important!